ProQR Therapeutics (PRQR) Payables (2021 - 2025)

ProQR Therapeutics' Payables history spans 4 years, with the latest figure at $17097.5 for Q4 2024.

  • For Q4 2024, Payables fell 98.97% year-over-year to $17097.5; the TTM value through Dec 2024 reached $17097.5, down 98.97%, while the annual FY2024 figure was $17317.4, 98.96% down from the prior year.
  • Payables for Q4 2024 was $17097.5 at ProQR Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Payables topped out at $5.7 million in Q4 2021 and bottomed at $17097.5 in Q4 2024.
  • The 4-year median for Payables is $1.0 million (2022), against an average of $1.9 million.
  • The largest annual shift saw Payables skyrocketed 314.57% in 2023 before it crashed 98.97% in 2024.
  • A 4-year view of Payables shows it stood at $5.7 million in 2021, then tumbled by 92.95% to $399937.0 in 2022, then soared by 314.57% to $1.7 million in 2023, then plummeted by 98.97% to $17097.5 in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Payables are $17097.5 (Q4 2024), $1.7 million (Q4 2023), and $399937.0 (Q4 2022).